Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Investigators Explore Immunotherapy for NETs as Incidence Grows

May 31st 2022

To date, oncologists have not seen much success with immunotherapy for neuroendocrine tumors.

FDA Approves 2 Frontline Nivolumab-Based Regimens for Unresectable Advanced or Metastatic ESCC

May 27th 2022

The FDA has approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 status.

Combinations Gain Momentum as First-Line Treatments for Unresectable Hepatocellular Carcinoma

May 25th 2022

A panel of hepatobiliary tumor experts discuss several pivotal phase 3 clinical trials examining combination approaches that have expanded or are anticipated to expand the treatment armamentarium for treatment-naïve patients with unresectable hepatocellular carcinoma.

FDA Grants Orphan Drug Designation to XMT-2056 for Gastric Cancer

May 19th 2022

The FDA has granted an orphan drug designation to XMT-2056 for use as a potential therapeutic option for patients with gastric cancer.

Nivolumab/Ipilimumab Plus SBRT Shows Antitumor Activity in Refractory Pancreatic Cancer

May 18th 2022

Stereotactic body radiation therapy in combination with nivolumab and ipilimumab demonstrated clinically meaningful antitumor activity with a favorable toxicity profile in difficult-to-treat patients with refractory metastatic pancreatic cancer, although the contribution of SBRT is still unclear.

Nihilism Remains a Barrier to Effective Treatment Delivery in Pancreatic Cancer

May 10th 2022

Jonathan Mizrahi, MD, discusses updates from the meeting in pancreatic cancer and hepatocellular carcinoma, the growing role of immunotherapy in GI cancer, and the ‘watch and wait’ protocol seen in rectal cancer

Lower Rates of Negative Surgical Margins Found in Black Patients Vs White Patients with GI Tract Cancer

May 10th 2022

Rates of negative surgical margins and adequate lymphadenectomies were lower in Black patients with gastrointestinal tract cancer compared with White patients, according to data from a retrospective cohort study published in JAMA Network Open.

Unmasking NETs Requires a Multifaceted Approach to Care

May 10th 2022

Eric Liu, MD, FACS, reviews treatment options, pitfalls of diagnoses, and the importance of involving specialists and advocates early in neuroendocrine tumors.

Racial Disparities Revealed in Surgical Outcomes in Gastrointestinal Tract Cancer

May 9th 2022

Sajid A. Khan MD, FACS, FSSO, discusses findings from the study on racial disparities in surgical outcomes and quality of care for GI tract cancer, plus what issues need to be addressed to close the gap in care.

Novartis Suspends Production of Radioligand Therapy Agents in New Jersey and Italy

May 9th 2022

Pharmaceutical giant Novartis has temporarily halted radioligand therapy production at sites in Millburn, New Jersey, and Ivrea, Italy, citing potential quality issues in its manufacturing processes.

CTX-009/Paclitaxel Combo Demonstrates Antitumor Activity, Favorable Tolerability in Biliary Tract Cancer

May 5th 2022

A novel combination comprised of the investigational bispecific antibody CTX-009 and paclitaxel was found to produce responses in 4 subtypes of biliary tract cancer with favorable safety and tolerability, according to interim results from an ongoing phase 2 trial.

FDA Grants Priority Review to Durvalumab/Chemo Combo for Locally Advanced or Metastatic Biliary Tract Cancer

May 4th 2022

The FDA has accepted a supplemental biologics license application and granted priority review to durvalumab in combination with standard gemcitabine and cisplatin for the treatment of patients with locally advanced or metastatic biliary tract cancer.

FDA Issues Complete Response Letter to Surufatinib for Advanced Neuroendocrine Tumors

May 2nd 2022

The FDA has issued a complete response letter to the new drug application seeking the approval of surufatinib for the treatment of patients with pancreatic and extra-pancreatic neuroendocrine tumors.

NCCN Establishes Standards of Care in Ampullary Adenocarcinoma

April 29th 2022

The National Comprehensive Cancer Network has released new guidelines for ampullary adenocarcinoma, a disease accounting for just 0.2% of all gastrointestinal malignancies.

Extended Follow-Up Confirms Survival Advantage of Adjuvant Capecitabine in Resected Biliary Tract Cancer

April 29th 2022

Adjuvant capecitabine continues to demonstrate an improvement in overall survival compared with observation following curative-intent resection in patients with biliary tract cancer.

European Commission Approves Pembrolizumab for Select MSI-H/dMMR Solid Tumors

April 29th 2022

The European Commission has granted an approval to pembrolizumab for the treatment of patients with select microsatellite instability–high or deficient mismatch repair solid tumors.

Dr. Maron on Sequencing Considerations in the Frontline Treatment of GI Cancers

April 28th 2022

Steven Maron, MD, MSc, discusses sequencing considerations in the frontline treatment of gastrointestinal cancers.

Dr. Khan on Racial Disparities with Patient Surgical Outcomes in GI Tract Cancer

April 28th 2022

Sajid A Khan MD, FACS, FSSO, discusses racial disparities with patient surgical outcomes in gastrointestinal tract cancer.

Frontline Tislelizumab/Chemo Combo Improves OS in Advanced Esophageal Squamous Cell Carcinoma

April 27th 2022

The combination of tislelizumab and chemotherapy resulted in a significant improvement in overall survival compared with chemotherapy alone in patients with locally advanced, recurrent or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 expression.

FDA Grants Priority Review to Tremelimumab/Durvalumab Regimen in Unresectable HCC

April 25th 2022

The FDA has accepted for priority review a biologics license application seeking the approval of a single priming dose of tremelimumab added to regular interval durvalumab in the treatment of patients with unresectable hepatocellular carcinoma.